Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03687294
Recruitment Status : Recruiting
First Posted : September 27, 2018
Last Update Posted : July 21, 2020
Sponsor:
Information provided by (Responsible Party):
Yousra Refaey, Cairo University

Brief Summary:
in this resarch we will use ELISA Technique to estimate Human Transcriptional Activator(MYB) Expression .compare it by Immmunohistochemistry analysis of MYB Expression in the malignant and benign salivary gland tumor

Condition or disease Intervention/treatment
Malignant Neoplasm of Salivary Gland Benign Neoplasm of Salivary Gland Device: enzyme linked immunosorbent assay (ELISA)

Layout table for study information
Study Type : Observational
Estimated Enrollment : 70 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas
Actual Study Start Date : January 12, 2019
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Group I
patients suffering from malignant salivary gland tumors.
Device: enzyme linked immunosorbent assay (ELISA)
ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors

Group II
patients suffering from benign salivary gland tumors.
Device: enzyme linked immunosorbent assay (ELISA)
ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors




Primary Outcome Measures :
  1. Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas [ Time Frame: two years ]
    Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Egyptian population
Criteria

Inclusion Criteria: .

  • Patients with clinically evident salivary gland tumors; malignant tumors will be recruited in group I
  • Benign tumors will be recruited in group II.

Exclusion Criteria:

  • Subjects taking any drugs inducing any changes that could affect the salivary glands.
  • Pregnant females.
  • Subjects having any allergies, infectious or autoimmune diseases.
  • Subjects having any metabolic disorders that can be manifested with salivary gland swelling as diabetes mellitus.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03687294


Contacts
Layout table for location contacts
Contact: yousra refaey 01014458092 yousrarefaey@yahoo.com
Contact: Fat'heya Zahran 01060775113 fatheya.zahran@dentistry.cu.edu.eg

Locations
Layout table for location information
Egypt
National Cancer Institute Recruiting
Cairo, Egypt, 11796
Contact    0223689711    webmaster@nci.cu.edu.eg   
Sponsors and Collaborators
Cairo University
Layout table for additonal information
Responsible Party: Yousra Refaey, pricipal investegator, Cairo University
ClinicalTrials.gov Identifier: NCT03687294    
Other Study ID Numbers: yousrarefaey11
First Posted: September 27, 2018    Key Record Dates
Last Update Posted: July 21, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Salivary Gland Neoplasms
Mouth Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Mouth Diseases
Stomatognathic Diseases
Salivary Gland Diseases